Medicus Pharma (MDCX) Competitors $2.29 -0.09 (-3.78%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MDCX vs. MCRB, CCCC, CRBP, ACTU, FATE, ANRO, CGEN, CRDF, PEPG, and NKTXShould you be buying Medicus Pharma stock or one of its competitors? The main competitors of Medicus Pharma include Seres Therapeutics (MCRB), C4 Therapeutics (CCCC), Corbus Pharmaceuticals (CRBP), Actuate Therapeutics (ACTU), Fate Therapeutics (FATE), Alto Neuroscience (ANRO), Compugen (CGEN), Cardiff Oncology (CRDF), PepGen (PEPG), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry. Medicus Pharma vs. Its Competitors Seres Therapeutics C4 Therapeutics Corbus Pharmaceuticals Actuate Therapeutics Fate Therapeutics Alto Neuroscience Compugen Cardiff Oncology PepGen Nkarta Medicus Pharma (NASDAQ:MDCX) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment. Do insiders and institutionals believe in MDCX or MCRB? 59.3% of Seres Therapeutics shares are owned by institutional investors. 11.2% of Medicus Pharma shares are owned by insiders. Comparatively, 4.7% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend MDCX or MCRB? Medicus Pharma currently has a consensus target price of $23.50, indicating a potential upside of 926.20%. Seres Therapeutics has a consensus target price of $14.33, indicating a potential downside of 27.24%. Given Medicus Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Medicus Pharma is more favorable than Seres Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.83Seres Therapeutics 3 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.60 Does the media refer more to MDCX or MCRB? In the previous week, Seres Therapeutics had 2 more articles in the media than Medicus Pharma. MarketBeat recorded 6 mentions for Seres Therapeutics and 4 mentions for Medicus Pharma. Seres Therapeutics' average media sentiment score of 0.82 beat Medicus Pharma's score of 0.50 indicating that Seres Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seres Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, MDCX or MCRB? Seres Therapeutics has higher revenue and earnings than Medicus Pharma. Seres Therapeutics is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedicus PharmaN/AN/A-$11.16M-$1.34-1.71Seres Therapeutics$126.32M1.36$140K-$4.60-4.28 Is MDCX or MCRB more profitable? Seres Therapeutics' return on equity of -350.16% beat Medicus Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Medicus PharmaN/A -549.30% -228.06% Seres Therapeutics N/A -350.16%-67.69% SummaryMedicus Pharma and Seres Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDCX vs. The Competition Export to ExcelMetricMedicus PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.40M$3.38B$6.11B$10.47BDividend YieldN/A2.29%5.73%4.77%P/E Ratio-1.718.3264.8323.34Price / SalesN/A488.16608.74136.45Price / CashN/A46.7037.4661.86Price / Book7.9010.5512.426.81Net Income-$11.16M-$52.58M$3.32B$276.80M7 Day Performance-6.91%1.09%1.01%0.27%1 Month Performance-7.66%16.09%10.75%8.31%1 Year PerformanceN/A18.41%76.20%35.60% Medicus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDCXMedicus Pharma2.776 of 5 stars$2.29-3.8%$23.50+926.2%N/A$42.40MN/A-1.71N/AAnalyst ForecastMCRBSeres Therapeutics2.1876 of 5 stars$19.77+0.6%$14.33-27.5%+17.8%$172.94M$126.32M-4.30330News CoveragePositive NewsCCCCC4 Therapeutics3.6552 of 5 stars$2.43+8.7%$8.50+250.5%-65.6%$172.59M$35.58M-1.53150CRBPCorbus Pharmaceuticals3.9546 of 5 stars$14.16+5.5%$45.43+220.9%-13.1%$172.25MN/A-2.9540News CoverageACTUActuate Therapeutics1.9165 of 5 stars$7.56+7.8%$20.33+169.0%+2.0%$171.63MN/A0.0010FATEFate Therapeutics3.8822 of 5 stars$1.48-2.3%$3.30+123.7%-50.8%$170.11M$13.63M-1.02550News CoverageANROAlto Neuroscience2.1856 of 5 stars$6.12-1.5%$9.80+60.3%-59.7%$164.11MN/A-2.54N/ACGENCompugen1.368 of 5 stars$1.83+0.8%$4.00+119.2%+25.6%$162.86M$27.86M-8.3070News CoverageCRDFCardiff Oncology2.5617 of 5 stars$2.46+3.4%$10.63+331.7%-13.7%$162.67M$680K-2.8120PEPGPepGen3.4743 of 5 stars$4.93+1.3%$8.40+70.2%-47.6%$162.20MN/A-1.6730NKTXNkarta2.4028 of 5 stars$2.29+9.3%$13.50+490.8%-39.3%$161.59MN/A-1.54140 Related Companies and Tools Related Companies Seres Therapeutics Alternatives C4 Therapeutics Alternatives Corbus Pharmaceuticals Alternatives Actuate Therapeutics Alternatives Fate Therapeutics Alternatives Alto Neuroscience Alternatives Compugen Alternatives Cardiff Oncology Alternatives PepGen Alternatives Nkarta Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDCX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
